Opus Genetics Files Q1 2025 10-Q

Ticker: IRD · Form: 10-Q · Filed: May 15, 2025 · CIK: 1228627

Sentiment: neutral

Topics: 10-Q, pharmaceuticals, financial-report

TL;DR

Opus Genetics filed its Q1 2025 10-Q. Financials and operations update.

AI Summary

Opus Genetics, Inc. filed its quarterly report for the period ending March 31, 2025. The company, formerly known as Ocuphire Pharma, Inc., is in the pharmaceutical preparations industry. The filing details financial information and operational updates for the first quarter of 2025.

Why It Matters

This filing provides investors with an update on Opus Genetics' financial health and operational progress during the first quarter of 2025, crucial for understanding the company's trajectory in the pharmaceutical sector.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Opus Genetics faces inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

Key Players & Entities

FAQ

What was the previous name of Opus Genetics, Inc.?

Opus Genetics, Inc. was formerly known as Ocuphire Pharma, Inc., with a name change effective November 9, 2020.

What is the Standard Industrial Classification (SIC) code for Opus Genetics, Inc.?

The SIC code for Opus Genetics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

What is the fiscal year end for Opus Genetics, Inc.?

The fiscal year end for Opus Genetics, Inc. is December 31.

What is the SEC file number for Opus Genetics, Inc.?

The SEC file number for Opus Genetics, Inc. is 001-34079.

What is the business address of Opus Genetics, Inc.?

The business address of Opus Genetics, Inc. is 8 Davis Drive, Suite 220, Durham, NC 27709.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 15, 2025 regarding Opus Genetics, Inc. (IRD).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing